Search research articles
Contact Us
Filters
Showing results (781-790 of 869) with videos related to
Page
of 87
Sort By:
Viruses
|
July 7, 2019
Combining Viral Genetics and Statistical Modeling to Improve HIV-1 Time-of-infection Estimation towards Enhanced Vaccine Efficacy Assessment
Raabya Rossenkhan, Morgane Rolland, Jan P L Labuschagne, et al.
Annals of Internal Medicine
|
April 12, 2021
A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated
Dean Follmann, Jonathan Fintzi, Michael P Fay, et al.
Pharmaceutics
|
May 25, 2024
Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIV
Bryan T Mayer, Lily Zhang, Allan C deCamp, et al.
Plos One
|
February 8, 2014
Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection
Susan Zolla-Pazner, Allan deCamp, Peter B Gilbert, et al.
Journal of Virology
|
August 17, 2012
Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family
Mattia Bonsignori, Justin Pollara, M Anthony Moody, et al.
Science Translational Medicine
|
May 6, 2011
Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys
Norman L Letvin, Srinivas S Rao, David C Montefiori, et al.
Statistical Communications in Infectious Diseases
|
December 9, 2017
Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials
Peter B Gilbert, Michal Juraska, Allan C deCamp, et al.
The New England Journal of Medicine
|
October 9, 2013
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine
Scott M Hammer, Magdalena E Sobieszczyk, Holly Janes, et al.
Vaccine
|
February 23, 2026
Impact of prior SARS-CoV-2 acquisition on binding and neutralizing antibody responses following COVID-19 vaccination: A cross-protocol analysis of individual-level data from six phase 3 clinical trials
Aaron Hudson, Scott Borgetti, Anne-Marie Rick, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 10, 2024
COVID-19 Vaccine Efficacy in Participants With Weakened Immune Systems From 4 Randomized Controlled Trials
Amy C Sherman, Jessica Tuan, Valeria D Cantos, et al.
Page
of 87
Search research articles
Search
Showing results (781-790 of 869) with videos related to
Sort By:
Page
of 87
Viruses
|
July 7, 2019
Combining Viral Genetics and Statistical Modeling to Improve HIV-1 Time-of-infection Estimation towards Enhanced Vaccine Efficacy Assessment
Raabya Rossenkhan, Morgane Rolland, Jan P L Labuschagne, et al.
Annals of Internal Medicine
|
April 12, 2021
A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated
Dean Follmann, Jonathan Fintzi, Michael P Fay, et al.
Pharmaceutics
|
May 25, 2024
Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIV
Bryan T Mayer, Lily Zhang, Allan C deCamp, et al.
Plos One
|
February 8, 2014
Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection
Susan Zolla-Pazner, Allan deCamp, Peter B Gilbert, et al.
Journal of Virology
|
August 17, 2012
Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family
Mattia Bonsignori, Justin Pollara, M Anthony Moody, et al.
Science Translational Medicine
|
May 6, 2011
Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys
Norman L Letvin, Srinivas S Rao, David C Montefiori, et al.
Statistical Communications in Infectious Diseases
|
December 9, 2017
Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials
Peter B Gilbert, Michal Juraska, Allan C deCamp, et al.
The New England Journal of Medicine
|
October 9, 2013
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine
Scott M Hammer, Magdalena E Sobieszczyk, Holly Janes, et al.
Vaccine
|
February 23, 2026
Impact of prior SARS-CoV-2 acquisition on binding and neutralizing antibody responses following COVID-19 vaccination: A cross-protocol analysis of individual-level data from six phase 3 clinical trials
Aaron Hudson, Scott Borgetti, Anne-Marie Rick, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 10, 2024
COVID-19 Vaccine Efficacy in Participants With Weakened Immune Systems From 4 Randomized Controlled Trials
Amy C Sherman, Jessica Tuan, Valeria D Cantos, et al.
Page
of 87